Solid lipid nanoparticles were developed in early 1990s as an alternative to other traditional colloidal carriers like liposomes, polymeric nanoparticles and emulsions. Nanotechnology, as defined by the National Nanotechnology Initiative (NNI), is the study and use of structures roughly in the size range of 1 to 1000 nm. Solid lipid nanoparticles (SLN) are rapidly developing field of nanotechnology with several potential applications in drug delivery and research. The ability to incorporate drugs into nanocarriers offers a new prototype in drug delivery that could use for drug targeting. Hence solid lipid nanoparticles hold great promise for reaching the goal of controlled and site specific drug delivery. The overall goal of nanotechnology is the same as that of medicine: to diagnose as accurately and early as possible and to treat as effectively as possible without any side effects using controlled and targeted drug delivery approach. the bioacceptable and biodegradable nature of SLNs makes them less toxic as compared to polymeric nanoparticles. Supplemented with small size which prolongs the circulation time in blood.
Loading....